Prolor Biotech inks agreement with Yeda
Under a limited option-to-license agreement from Yeda, Prolor has been developing oxyntomodulin peptide, a drug compound using this technology as a treatment of obesity and has now exercised
Mediar Therapeutics has announced a collaboration and option agreement with Ono Pharmaceutical to develop new treatments for fibro-inflammatory diseases.